Lipoprotein-associated phospholipase A2 (Lp-PLA2) – possible diagnostic and risk biomarker in chronic ischaemic heart disease

In a group of 208 patients with chronic ischaemic heart disease, the variation of A(2)-associated-LDL phosphatase (Lp-PLA(2)) serum concentration values was analysed in dynamics at a two-week interval. The conclusion of the study is that the values of serum concentration of Lp-PLA(2) can be accepted...

Descripción completa

Detalles Bibliográficos
Autores principales: Diaconu, Adriana, Coculescu, Bogdan-Ioan, Manole, Gheorghe, Vultur, Horațiu, Coculescu, Elena Claudia, Stocheci, Cristina Maria, Tudorache, Ioan-Sorin, Dincă, Alexandra-Ligia, Dincă, Valeriu Gabi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7671608/
https://www.ncbi.nlm.nih.gov/pubmed/33187461
http://dx.doi.org/10.1080/14756366.2020.1839447
Descripción
Sumario:In a group of 208 patients with chronic ischaemic heart disease, the variation of A(2)-associated-LDL phosphatase (Lp-PLA(2)) serum concentration values was analysed in dynamics at a two-week interval. The conclusion of the study is that the values of serum concentration of Lp-PLA(2) can be accepted as a biomarker with diagnostic specificity for chronic ischaemic heart disease, a parameter of real utility in medical practice, both in situations where the patient, although clinically reporting the existence of angina pectoris, does not show specific changes on an EKG, and for the assessment of the response to personalised therapy.

Ejemplares similares